PURPOSE: To analyse the influence of cancer-associated stroma on FDG-uptake in two carcinoma models characterized by different stromal degrees. METHODS: Eight nude mice were subcutaneously injected with DU-145 prostate cancer cells or BXPC-3 pancreatic cancer cells, and underwent FDG-PET imaging about 2 weeks after implantation. After the mice were killed, histology, and CD31 and GLUT1 immunohistochemistry were performed. To further evaluate the highly stromalized carcinoma using perfusion-sensitive imaging, four BXPC-3 tumours underwent two successive albumin-binding (MS-325) MRI scans during tumour growth. RESULTS: FDG uptake was significantly higher in the DU-145 than in the BXPC-3 tumours, which were hardly distinguishable from adjacent normal tissue. In the BXPC-3 tumours, histology confirmed the widespread presence of aberrant infiltrated stroma, embedded with numerous vessels marked by CD31. In both tumour types, the stromal matrix was negative for GLUT1. In DU-145 tumour cells, GLUT1 immunostaining was greater than in BXPC-3 tumour cells, but not homogeneously, since it was less evident in the tumour cells which were nearer to vessels and stroma. Finally, MS-325 MRI always clearly showed areas of enhancement in the BXPC-3 tumours. CONCLUSION: Cancer-associated stroma has been reported to be capable of aerobic metabolism with low glucose consumption. Furthermore, it has been proposed that regions with high vascular perfusion exhibit a significantly lower FDG uptake, suggesting some vascular/metabolic reciprocity. Since our results are consistent with these recent findings, they signal a risk of tumour volume underestimation in radiotherapy if FDG uptake alone is used for target delineation of carcinomas, which suggests that additional evaluation should be performed using vasculature/perfusion-sensitive imaging.
PURPOSE: To analyse the influence of cancer-associated stroma on FDG-uptake in two carcinoma models characterized by different stromal degrees. METHODS: Eight nude mice were subcutaneously injected with DU-145 prostate cancer cells or BXPC-3 pancreatic cancer cells, and underwent FDG-PET imaging about 2 weeks after implantation. After the mice were killed, histology, and CD31 and GLUT1 immunohistochemistry were performed. To further evaluate the highly stromalized carcinoma using perfusion-sensitive imaging, four BXPC-3 tumours underwent two successive albumin-binding (MS-325) MRI scans during tumour growth. RESULTS:FDG uptake was significantly higher in the DU-145 than in the BXPC-3 tumours, which were hardly distinguishable from adjacent normal tissue. In the BXPC-3 tumours, histology confirmed the widespread presence of aberrant infiltrated stroma, embedded with numerous vessels marked by CD31. In both tumour types, the stromal matrix was negative for GLUT1. In DU-145 tumour cells, GLUT1 immunostaining was greater than in BXPC-3 tumour cells, but not homogeneously, since it was less evident in the tumour cells which were nearer to vessels and stroma. Finally, MS-325 MRI always clearly showed areas of enhancement in the BXPC-3 tumours. CONCLUSION:Cancer-associated stroma has been reported to be capable of aerobic metabolism with low glucose consumption. Furthermore, it has been proposed that regions with high vascular perfusion exhibit a significantly lower FDG uptake, suggesting some vascular/metabolic reciprocity. Since our results are consistent with these recent findings, they signal a risk of tumour volume underestimation in radiotherapy if FDG uptake alone is used for target delineation of carcinomas, which suggests that additional evaluation should be performed using vasculature/perfusion-sensitive imaging.
Authors: Anna C Pfannenberg; Philip Aschoff; Klaus Brechtel; Mark Müller; Roland Bares; Frank Paulsen; Jutta Scheiderbauer; Godehard Friedel; Claus D Claussen; Susanne M Eschmann Journal: Eur J Nucl Med Mol Imaging Date: 2006-08-01 Impact factor: 9.236
Authors: Michael I Koukourakis; Alexandra Giatromanolaki; Adrian L Harris; Efthimios Sivridis Journal: Cancer Res Date: 2006-01-15 Impact factor: 12.701
Authors: Kenneth J Biehl; Feng-Ming Kong; Farrokh Dehdashti; Jian-Yue Jin; Sasa Mutic; Issam El Naqa; Barry A Siegel; Jeffrey D Bradley Journal: J Nucl Med Date: 2006-11 Impact factor: 10.057
Authors: Jason L J Dearling; Aiden A Flynn; Julie Sutcliffe-Goulden; Ingrid A Petrie; Robert Boden; Alan J Green; Geoffrey M Boxer; Richard H J Begent; R Barbara Pedley Journal: J Nucl Med Date: 2004-01 Impact factor: 10.057
Authors: Anu Autio; Tiina Ujula; Pauliina Luoto; Satu Salomäki; Sirpa Jalkanen; Anne Roivainen Journal: Eur J Nucl Med Mol Imaging Date: 2010-06-04 Impact factor: 9.236
Authors: Federico Boschi; Laura Calderan; Daniela D'Ambrosio; Mario Marengo; Alberto Fenzi; Riccardo Calandrino; Andrea Sbarbati; Antonello E Spinelli Journal: Eur J Nucl Med Mol Imaging Date: 2010-09-30 Impact factor: 9.236
Authors: T Yu; G Yang; Y Hou; X Tang; C Wu; X-A Wu; L Guo; Q Zhu; H Luo; Y-E Du; S Wen; L Xu; J Yin; G Tu; M Liu Journal: Oncogene Date: 2016-10-10 Impact factor: 9.867
Authors: Maria Bjurberg; Parisa Abedinpour; Eva Brun; Bo Baldetorp; Per Borgström; Johan Wennerberg; Elisabeth Kjellén Journal: Nucl Med Mol Imaging Date: 2010-06-09